Illustrative

New CTIM-76 data show tumor responses in platinum-resistant ovarian cancer

Stock Titan·Jun 15

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Data from the ctim-76 study has shown tumor responses in patients with platinum-resistant ovarian cancer. The study's results indicate some level of effectiveness of ctim-76 in treating this type of cancer. The data suggests that ctim-76 may be a potential treatment option for patients with platinum-resistant ovarian cancer.

Full coverage

Context Therapeutics Reports 29% Response Rate for CTIM-76 in Platinum-Resistant Ovarian Cancer Phase 1 Trial

BioPharm International·Jun 16

Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer

Stock Titan·Jun 15

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

Benzinga·Jun 15

FDA Grants Fast Track Designation to CTIM-76 for Platinum-Resistant Ovarian Cancer

OncLive·Apr 2

CTIM-76 Receives FDA FTD for Platinum-Resistant Ovarian Cancer

Cure Today·Apr 3

FDA Fast Track Designation for Oncology Drugs in April 2026

Oncology News Central·May 4

CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip

Stocktwits·Jun 15

FDA fast-tracks Context drug for hard-to-treat ovarian cancer

Stock Titan·Apr 2

View original report at Stock Titan ↗

Fetching the latest headlines…